A Study to Investigate the Effects of CBP-307 on the Heart-corrected QT Interval (QTc) Interval in Healthy Subjects
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Autoimmune Diseases
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 60 years
- Gender
- Both males and females
Description
This will be a Phase I, randomized, double-blind, double-dummy, placebo-controlled, positive-controlled, single-site study to investigate the effects of therapeutic and supratherapeutic oral doses of CBP-307 on the QTc interval in healthy male and female subjects. The study is divided into a treatme...
This will be a Phase I, randomized, double-blind, double-dummy, placebo-controlled, positive-controlled, single-site study to investigate the effects of therapeutic and supratherapeutic oral doses of CBP-307 on the QTc interval in healthy male and female subjects. The study is divided into a treatment period of 18 days and a follow-up period of 12 ± 2 days.
Tracking Information
- NCT #
- NCT04818229
- Collaborators
- Not Provided
- Investigators
- Study Director: Suzhou Connect Suzhou Connect Biopharmaceuticals, Ltd.
Get Well Soon